Tumor Mutational Burden as a Pan-cancer Biomarker for Immunotherapy: The Limits and Potential for Convergence.

Details

Request a copyRequest a copy
Serval ID
serval:BIB_BE5AFDD22C20
Type
Article: article from journal or magazin.
Publication sub-type
Letter (letter): Communication to the publisher.
Collection
Publications
Institution
UNIL/CHUV
Title
Tumor Mutational Burden as a Pan-cancer Biomarker for Immunotherapy: The Limits and Potential for Convergence.
Journal
Cancer cell
Author(s)
Passaro A., Stenzinger A., Peters S.
ISSN
1878-3686 (Electronic)
ISSN-L
1535-6108
Publication state
Published
Issued date
09/11/2020
Peer-reviewed
Oui
Volume
38
Number
5
Pages
624-625
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
A recent study in The Lancet Oncology reports that high tumor mutational burden (TMB) is associated with response to anti-PD-1 pembrolizumab, leading to the second FDA approval of a tissue-agnostic predictive biomarker for immunotherapy in solid tumors. This is a step forward in realizing the full potential of cancer immunotherapy.
OAI-PMH
oai:serval.unil.ch:BIB_BE5AFDD22C20
DOI
10.1016/j.ccell.2020.10.019
Pubmed
33171127
Web of science
000589896200011
Create date
16/11/2020 14:33
Last modification date
16/12/2020 6:24
Usage data